Women with polycystic ovary syndrome have a higher risk of insulin resistance, dyslipidemia, and prothrombotic states compared to matched controls, increasing cardiometabolic disease risk.
Women with PCOS have an increased risk of cardiometabolic alterations, including insulin resistance, dyslipidemia, and cardiovascular disease, highlighting the need for targeted therapeutic strategies.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder amongst women of reproductive age and is associated with various metabolic perturbations, in addition to chronic anovulation and factors related to androgen excess. In general, women live longer than men and develop cardiovascular disease at an older age. However, women with PCOS, as compared with age- and body mass index-matched women without the syndrome, appear to have a higher risk of insulin resistance, hyperinsulinemia, glucose intolerance, dyslipidemia, and an increased prothrombotic state, possibly resulting in a higher rate of type 2 diabetes mellitus, fatty liver disease, subclinical atherosclerosis, vascular dysfunction, and finally cardiovascular disease and mortality. Further alterations in PCOS include an increased prevalence of sleep apnea, as well as various changes in the secretion and/or function of adipokines, adipose tissue-derived proinflammatory factors and gut hormones, all of them with direct or indirect influences on the complex signaling network that regulates metabolism, insulin sensitivity, and energy homeostasis. Reviews on the cardiometabolic aspects of PCOS are rare, and our knowledge from recent studies is expanding rapidly. Therefore, it is the aim of the present review to discuss and to summarize the current knowledge, focusing on the alterations of cardiometabolic factors in women with PCOS. Further insight into this network of factors may facilitate finding therapeutic targets that should ameliorate not only ovarian dysfunction but also the various cardiometabolic alterations related to the syndrome.
Randeva et al. (Tue,) conducted a review in Polycystic Ovary Syndrome. Women with polycystic ovary syndrome have a higher risk of insulin resistance, dyslipidemia, and prothrombotic states compared to matched controls, increasing cardiometabolic disease risk.